Study of IMC-P115C in Advanced PRAME-Positive Cancers

This study tests a new cancer treatment called IMC-P115C, which is designed to help the immune system recognize and attack cancer cells that carry a protein called PRAME. This is an early-phase trial for people with advanced solid tumors that have not responded to other treatments. **You may be eligible if...** - You have a metastatic or inoperable solid tumor that tests positive for PRAME - Your cancer has relapsed, is resistant to, or you are intolerant of all available standard treatments - You have a specific immune system marker called HLA-A*02:01 (determined by a blood test) - You are in good overall physical condition (ECOG 0 or 1) **You may NOT be eligible if...** - You have untreated or actively symptomatic brain metastases - You had a bowel obstruction, perforation, or fistula within the past 3 months - You require ongoing drainage of fluid buildup in your abdomen or chest - You have significant heart, lung, or autoimmune disease - You require immune-suppressing medications - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.